SUBSCRIBE
SUBSCRIBE

Alzheon

NEWS
Drug Development
Mereo BioPharma’s Rationale for Halting IPO Draws Skepticism
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
April 27, 2018
 · 
2 min read
 · 
Mark Terry
The Top 6 Global Generic Drug Companies to Work Fo
Drug Development
Alzheon Launches IPO to Fund Alzheimer’s Drug
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
March 19, 2018
 · 
2 min read
 · 
Mark Terry
Business
Top 20 Life Science Startups to Watch in the U.S.
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
January 26, 2016
 · 
15 min read
 · 
Mark Terry
What You Need to Know About Alzheon
Business
What You Need to Know About Alzheon
December 17, 2015
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Raising $10M in Series A, Alzheon CEO Bets He Can Beat Biogen With World’s First Alzheimer’s Drug
April 8, 2015
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2016
JOBS
IN THE PRESS
Press Releases
Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois
April 14, 2026
 · 
12 min read
Press Releases
Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism
April 7, 2026
 · 
10 min read
Press Releases
Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark
March 10, 2026
 · 
11 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
December 2, 2025
 · 
12 min read
Press Releases
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
October 15, 2025
 · 
12 min read
Press Releases
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
July 15, 2025
 · 
12 min read
Press Releases
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
April 10, 2025
 · 
13 min read
Press Releases
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
March 18, 2025
 · 
10 min read
Press Releases
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
February 25, 2025
 · 
11 min read
Load More